Anthony J. Senagore, M.D., is an colorectal surgeon with a long track record of academic surgery practice. He has served as Professor of Surgery at a number of prestigious academic medical centers including UTMB at Galveston, Central Michigan University, College of Medicine, the University of Southern California, Keck School of Medicine, Cleveland Clinic Foundation and Spectrum Health/Michigan State University. He has served as Chair of the Colorectal Surgery Residency Review Committee for the ACGME, President of the Board of Colon and Rectal Surgery and Past President of the ASCRS and Midwest Surgical Association. He also served on the Relative Value Update Committee for 16 years and as Chair of the Practicing Physicians Advisory Committee for the Centers for Medicaid Services. He has significant experience in revenue cycle and capacity management for health care. In addition, during his career he was involved in the development of many innovations in laparoscopic colorectal surgery and the field of enhanced recovery.
Dr. Senagore earned his medical degree from Michigan State University (MSU), East Lansing, MI. He completed his residency in General Surgery at the Butterworth Hospital/MSU program in Grand Rapids, MI. Dr. Senagore then completed a research fellowship and colon and rectal surgery residency at Ferguson Hospital on the Grand Rapids and East Lansing campuses of MSU. He continued his education and later received his Master of Science degree in physiology from MSU and a Master of Business Administration from the University of Phoenix, San Francisco, CA campus. He has edited 5 textbooks in colon and rectal surgery, authored over 230 peer-reviewed publications and 25 textbook chapters.
Head of Cardiothoracic Surgery in Poria Medical Center, Israel, Deputy director of the Department of cardiac surgery at the Sheba Medical Center, and the Chief Manager of the Wounds Clinic for Post-cardiac Surgery and the CEO, medical director and senior surgeon in the Cardioheal group. He is also a supervisor of students and lecturer of several courses at the Tel Aviv University. Dr. Kachel is responsible for changing the therapeutic approach to thoracic infection treatment for patients both here and abroad, by providing significantly improved survival rates and better quality of life for these patients. He has published many articles on this subject in international medical journals. Dr. Kachel did his clinical fellowship in the cardiovascular department at the SunnyBrook M edical Center in Toronto Canada between the tears 2009-20011, did his cardiothoracic surgery residency at the Sheba Medical Center and graduated Medical School at the Ben Gurion University of the Negev.
Dr. Schaff is the Stuart W. Harrington Professor of Surgery and a consultant in the Division of Cardiovascular Surgery at Mayo Clinic, Rochester, Minnesota. He is a member of major international societies, including the American Association for Thoracic Surgery (2012-2013 President). He has authored or co-authored 784 papers, 94 book chapters, edited or written 9 textbooks and delivered over 500 lectures. He has served or is serving on the editorial boards of 11 journals including Circulation and the Journal of Thoracic and Cardiovascular Surgery, where he is currently the Associate Editor. Dr. Schaff received his medical degree and training at the University Of Oklahoma School Of Medicine where he also completed an NIH Research Fellowship. His surgical training was completed at Johns Hopkins Hospital.
Former chairman and professor of the orthopedic surgery department, Hadassah Medical Center, Jerusalem, Israel. Before that, he was chairman and director the orthopedic department of Boston City Hospital (BCH), Boston, MA. Prof. Segal serves on the medical advisory board of a number of startup companies.
Professor of orthopedics at the University of Minnesota, and a member of the top leadership of the university’s orthopedic surgery department. Prof. Gustilo was the founding president of the Orthopedic Trauma Hospital Association and the Orthopedic Trauma Association in the US. He holds 13 patents, designed one of the earliest knee replacements (Gustilo knee), and the first hip replacement approved by the FDA for use without bone cement (BIAS Hip). One of Prof. Gustilo’s contributions to the orthopedic world was the classification, together with other orthopedic experts, of open tibial fractures, and the recommended treatment based on this classification that was instrumental in improving care of severe fractures. This classification is still used by trauma and orthopedic surgeons worldwide.
Director of clinical and transitional research development for New York University Langone’s department of orthopedic surgery. He is also professor of orthopedic surgery at NYU School of Medicine.
Recently, Dr. Einhorn served as chair of the department of orthopedic surgery at Boston Medical Center and professor of orthopedic surgery, biochemistry and biomedical engineering at the Boston University School of Medicine.
Dr. Einhorn received his medical degree from Cornell University Medical College in New York City. He completed his residency at St. Luke’s – Roosevelt Hospital Center and Columbia University in New York City, and his post-doctoral fellowship at The Hospital for Special Surgery in New York City.
Head of the orthopedic division of the Tel-Aviv Sourasky Medical Center (Ichilov), a Level-1 trauma center, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University. Prof. Salai, completed his training at the, Sheba Medical Center, Israel, then served as the head of orthopedic department at the Beilinson Hospital, Rabin Medical Center, Israel and in his current position since 2010. Prof. Salai has extensive clinical and scientific experience, with over 120 PubMed cited publications. He is the head of the Israel Association of Tissue Banking, and the Israel Medical Association Council, and formerly was the president of the EATB (European Association of Tissue Banks).
Dr. Egol is a Professor of Orthopaedic Surgery and Chief of Orthopaedic Trauma Surgery at NYU Langone Health. He is fellowship trained in orthopaedic traumatology and manages Gustillo Grade III open long bone fractures on a routine basis. He will have overall responsibility for this multi-center project with a special emphasis on managing the various aspects of the project for all clinical sites that are enrolling patients. Dr. Egol has helmed several research trials conducted at NYU Langone Medical over his 19 year career. As a graduate of Binghamton, Dr. Egol completed his residency in orthopaedic surgery at the Hospital for Joint Diseases. He currently sits on the editorial board of several medical journals, and has authored 4 textbooks, contributed 25 textbook chapters and over 200 scientific articles. Today, he maintains an active clinical practice specializing in orthopaedic trauma and fracture, performing over 450 operative procedures each year.
Dr. Zvi Metzger is professor of endodontology and associate professor of oral biology at Tel Aviv University, where he served as dean (1987-1991) and director of research laboratories (1981-2010) of the School of Dental Medicine. Recently he served there as chair of department of endodontology. Prof. Metzger is author of chapters in the leading textbooks of endodontology and published extensively in the fields of oral biology and endodontology. He has experience as scientific advisor to several start-up companies.
Dr. Stark is Vice President of Global Clinical Development at Teva Pharmaceutical Industries, Ltd. Dr Stark is pioneer and Expert in Global Clinical Development Strategy. Dr. Stark joined Teva in 1987. From 1991 to 1994 she was based in the US, where she established the Innovative R&D Division of Teva USA and was responsible for the clinical development of Copaxone®. Upon her return back to Israel, she has continued in building up the Global Clinical Infrastructures of Teva and was responsible also for the Clinical Development of other Teva products. . During her long term career in the industry , Dr Stark was involved in building up new clinical therapeutic areas such as Oncology and Biosmilars as well as advancing new technologies into clinical trials. Dr. Stark holds a Ph.D. degree in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science.